AstraZeneca's Fasenra misses the primary COPD endpoint while Saphnelo's lupus trial shows significant improvements and ...

AstraZeneca ( NASDAQ: AZN) said that the late-stage trial for its medication Fasenra (benralizumab) in patients suffering ...

The RESOLUTE phase III trial of AstraZeneca’s Fasenra (benralizumab), despite showing numerical improvement, did not achieve statistical significance in the primary endpoint in patients with chronic ...

A molecular allergy chip reliably detected allergic asthma, revealing that 73% of the study's asthma cohort had sensitization ...

AstraZeneca (AZN) announced on Wednesday that its late-stage trial of Fasenra in patients with chronic obstructive pulmonary ...

A new study reveals that small cell lung cancer (SCLC) likely begins in basal stem-like cells rather than in neuroendocrine ...

Topline data were announced from a phase 3 trial evaluating efzofitimod in patients with pulmonary sarcoidosis.

Dr. Ross Camidge has helped treat thousands of lung cancer patients. Now, in a crazy life twist, Camidge is a lung cancer patient himself.

Regular physical activity reduces the risk of chronic obstructive pulmonary disease (COPD)1 and improves the prognosis in affected patients.2 In contrast, ambient air pollution, is a substantial risk ...